Andrew Alliance and Sartorius collaborate to provide software-connected pipettes for life science research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Andrew Alliance and Sartorius have launched the Andrew Alliance Pipette+ system, which uniquely provides both full traceability and improved repeatability in manual pipetting for life science laboratories. Andrew Alliance, the robotics company with an innovative approach to liquid handling that is improving repeatability of conventional laboratory pipettes, and the Life Science company Sartorius, are collaborating to bring this intelligent pipetting solution to market.
As much as half of all research funding in life sciences is used to repeat experiments, showing that lack of reproducibility in research is an ongoing challenge in the biopharmaceutical industry. A major cause of irreproducibility has been incorrect execution in liquid handling workflows. This collaboration between Andrew Alliance and Sartorius reflects both companies’ strategic investment in designing innovative pipetting solutions to improve reproducibility and simplify the complex and time-consuming workflows.
The Andrew Alliance Pipette+ system comprises several components that communicate with one another: electronic single and multichannel pipettes, an intelligent stand, and novel cloud-based software. Andrew Alliance co-developed the Pipette+ system with Sartorius, who is manufacturing the pipette hardware. The hardware is based on Sartorius’s Picus range of award-winning, ergonomic electronic pipettes. Using current-day Internet of Things (IoT) solutions, the pipettes communicate wirelessly with the stand by Bluetooth, and the computerized charging stand communicates with Cloud servers by either Wi-Fi or Ethernet. The pipette transmits data to the stand, such as possible errors, operator identity, and step-by-step actions taken by the operator, ensuring full traceability and improved repeatability.
The software system uses Andrew Alliance’s free, browser-based intelligent software environment, OneLab. This software allows intuitive protocol design and simplified protocol execution. For instance, the software can indicate which pipette is to be used at each step in an experiment, preset the required pipetting parameters, and eject tips at the appropriate time. Thus, users can complete protocols in a few clicks. The Andrew Alliance Pipette+ system, therefore, combines the best-in-class pipetting performance, and excellent ergonomics Sartorius’ pipettes are known for, with intelligent software.
“We worked together with Andrew Alliance to provide the scientific community with a next-generation solution for manual pipetting. We’ve been at the forefront of the electronic pipette revolution with our Picus pipette and are now connecting the world of pipetting to the world of computing. This represents a quantitative leap in the performance of electronic pipettes over that of mechanical devices,” says Venkat Rao, Head Business Management, EMEA Life Science Research at Sartorius.
“Life science researchers should be confident that their often highly limited biological samples, costly reagents and time, are focused on progressing valuable research rather than unnecessarily repeating experiments,” said Piero Zucchelli, CEO and co-founder of Andrew Alliance. “Andrew Alliance and Sartorius, the market leader in electronic pipettes, are addressing the manual liquid handling repeatability problem head on.”
Enabled by this collaboration, Andrew Alliance has launched a larger family of collaborative products serving the life-science research market at the recent Society for Laboratory Automation and Screening Trade Show in Washington DC, at which it won a New Product Award for Pipette+.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...